CD8A and neoplasm: To determine if impaired anti-tumor immunity was related to CD8+ T cell function, Depdc5ncl, and Depdc5tko tumor-bearing mice were next treated intraperitoneal (I.P.)injection with anti-CD8 depletion antibody (250 μg per mouse per time point) or a control antibody at days 3, 6, and 9 after tumor inoculation.